RxDoctor Payments Data

Paul Carpenter

Pediatric Hematology-Oncology · Seattle, WANPI 1073695128

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $27,074 of the $39,710 with a category attached, or 68.2%. 6 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 32.6% of the total. 2025 is the largest year on record at $17,183, more than ten times the $1,010 reported in 2021. Among pediatric hematology-oncology clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$39,710in general payments, 2019–2025

Across 26 payments — averaging $1527.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$13K
  • Mesoblast, Inc.$11K
  • Incyte Corporation$9K
  • Sanofi$6K
  • Janssen Scientific Affairs, LLC$1K
  • Jazz Pharmaceuticals Inc.$109
$245,081in research payments, 2019–2025

Across 55 payments — averaging $4456.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Mallinckrodt Enterprises LLC$96K
  • Incyte Corporation$93K
  • Pharmacyclics LLC, An Abbvie Company$47K
  • AbbVie$10K

What the payments were for

  • Consulting fees$27,07468%
  • Speaking & faculty fees$8,47521%
  • Travel & lodging$3,4069%
  • Food & beverage$7542%

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$39,710 in reported general payments places this provider in the 90th percentile of 60 pediatric hematology-oncology providers in Washington.

See all pediatric hematology-oncology providers in Washington

Medicare billing

Part B allowed, 2024
$13,931
Medicare patients
34
Services billed
238

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pediatric hematology-oncology in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →